

ACCEPTANCE OF NEW ZEALAND PATENT APPLICATION

MELBOURNE (AUSTRALIA) 23 June 2020: Invion Limited (ASX: IVX) ("Invion" or "Company") is pleased to announce that the New Zealand patent office has accepted a patent covering a key input used in the IVX-PDT photodynamic cancer treatments being developed by the Company, based on Photosoft™ technology licenced from RMW Cho Group.

The patent relates to the chlorin e4 sodium photosensitiser and a process for its preparation. Invion believes that the use of the chlorin e4-based photosensitiser has key advantages over other earlier photodynamic technologies.

These advantages include activation at a higher wavelength allowing for deeper tissue penetration, more rapid clearance from cells (thus limiting ongoing photo-sensitivity) and lack of observable "dark toxicity" in the absence of light activation (meaning the photosensitiser remains benign unless activated by a specific wavelength of light).

As announced to the market in February 2020, a presentation to the Lorne Cancer Conference of initial independent animal tests by Hudson Institute of Medical Research confirmed that Photosoft™ technology caused substantial inflammation and necrosis of tumour tissue after two days in an ovarian cancer model with a reduction in tumour burden by >50% after three weeks.

Invion is on track to start human trials for its skin cancer treatment in late 2020 or early 2021.

About the Patent

Title of Invention: Chlorin derivative useful in photodynamic therapy and diagnosis

NZ Patent Number: 749124

Applicant: RMW Cho Group Limited

A patent on this application is due to grant in New Zealand following 26 September 2020 provided no opposition or re-examination is commenced. Once granted, the patent will have an expiry date of 13 December 2033.

Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. The Australian patent (Patent Number: 2013357030) currently has an expiry date of 13 December 2033.

Investor enquiries

Managing Director & CEO, Craig Newton

T: +61 3 9081 6005

E: investor@inviongroup.com

Media enquiries

Brendon Lau

T: 0409 341 613

E: brendon@vantagepointpartners.com.au

ASX ANNOUNCEMENT

About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by Craig Newton, MD & CEO. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.